Stockscreener 앱 받기
14.17
9.08%
1.18
시장 영업 전:
14.30
0.13
+0.92%
Trevi Therapeutics Inc 주식(TRVI)의 최신 뉴스
Marshall Wace LLP Has $13.55 Million Stock Position in Trevi Therapeutics, Inc. $TRVI - MarketBeat
Trevi Therapeutics (NASDAQ:TRVI) Hits New 12-Month HighTime to Buy? - MarketBeat
Trevi Therapeutics (NASDAQ:TRVI) Trading 5.7% HigherTime to Buy? - MarketBeat
Trevi Therapeutics stock hits all-time high of 14.01 USD - Investing.com
Trevi Therapeutics stock hits all-time high of 14.01 USD By Investing.com - Investing.com Australia
Trevi Therapeutics, Inc. $TRVI Shares Acquired by Vivo Capital LLC - MarketBeat
226,381 Shares in Trevi Therapeutics, Inc. $TRVI Bought by Prudential Financial Inc. - MarketBeat
Trevi Therapeutics Appoints New Chief Financial Officer - The Globe and Mail
Affinity Asset Advisors LLC Raises Holdings in Trevi Therapeutics, Inc. $TRVI - MarketBeat
Trevi Therapeutics appoints David Hastings as chief financial officer By Investing.com - Investing.com Nigeria
Trevi Therapeutics, Inc. Announces Appointment of David Hastings as Chief Financial Officer, Effective January 6, 2026 - marketscreener.com
Trevi Therapeutics, Inc. Announces the Hiring of David Hastings to Serve as the Company?s Principal Financial Officer, Effective January 6, 2026 - marketscreener.com
New Haven biotech names new CFO - Hartford Business Journal
Trevi Therapeutics appoints David Hastings as chief financial officer - Investing.com
Trevi Therapeutics, Inc. $TRVI Shares Purchased by Geode Capital Management LLC - MarketBeat
Trevi Therapeutics appoints David Hastings as new CFO By Investing.com - Investing.com Nigeria
Trevi Therapeutics Taps David Hastings as CFO - Contract Pharma
Trevi Therapeutics appoints David Hastings as new CFO - Investing.com India
Trevi Therapeutics, Inc. $TRVI Shares Purchased by Panagora Asset Management Inc. - MarketBeat
Trevi Therapeutics Names David Hastings CFO - marketscreener.com
Trevi Therapeutics announces appointment of David Hastings as chief financial officer - marketscreener.com
Trevi Therapeutics Announces Appointment Of David Hastings As Chief Financial Officer - TradingView
Trevi Therapeutics Announces Appointment of David Hastings as Chief Financial Officer - cnhinews.com
Trevi Therapeutics: "Buy" Rating For Haduvio Treating Chronic Cough In IPF And Beyond - Seeking Alpha
Trevi Therapeutics stock hits all-time high at 13.92 USD By Investing.com - Investing.com Canada
Trevi Therapeutics stock hits all-time high at 13.92 USD - Investing.com India
Trevi Therapeutics Draws Interest As Clinical Programs Move Forward - Kalkine Media
Trevi Therapeutics (TRVI) Rises on Takeover Speculation - GuruFocus
Trevi Therapeutics edges higher amid takeover speculation - MSN
Trevi Therapeutics edges higher amid takeover speculation (TRVI:NASDAQ) - Seeking Alpha
Trevi Therapeutics (TRVI) Stock Analysis Report | Financials & Insights - Benzinga
Jefferies Financial Group Inc. Makes New Investment in Trevi Therapeutics, Inc. $TRVI - MarketBeat
Trevi Therapeutics Inc Strengthens Strategy For Clinical Design - Kalkine Media
Tejara Capital Ltd Purchases 146,879 Shares of Trevi Therapeutics, Inc. $TRVI - MarketBeat
Trevi Therapeutics (NASDAQ:TRVI) Sets New 52-Week HighStill a Buy? - MarketBeat
Stocks of Trevi Therapeutics Inc (TRVI) are poised to climb above their peers - Setenews
Trevi Therapeutics stock hits all-time high at 12.31 USD By Investing.com - Investing.com India
Trevi Therapeutics stock hits all-time high at 12.31 USD - Investing.com
AXQ Capital LP Invests $227,000 in Trevi Therapeutics, Inc. $TRVI - MarketBeat
Trevi Therapeutics’ Earnings Call Highlights Promising Outlook - MSN
The Bull Case For Trevi Therapeutics (TRVI) Could Change Following Narrowed Losses and New Shelf Registration - simplywall.st
Chronic Refractory Cough Market is Expected to Boom by 2034 Driven by Advancements in Treatment Options | DelveInsight - GlobeNewswire Inc.
MAI Capital Management Sells 537,497 Shares of Trevi Therapeutics, Inc. $TRVI - MarketBeat
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Given Average Rating of "Buy" by Analysts - MarketBeat
Leerink Partnrs Has Bullish Outlook for TRVI FY2025 Earnings - MarketBeat
B. Riley Increases Earnings Estimates for Trevi Therapeutics - MarketBeat
B. Riley Predicts Increased Earnings for Trevi Therapeutics - Defense World
Trevi Therapeutics targets multiple phase III trial launches for chronic cough indications in 2026 as regulatory plans accelerate - MSN
Leerink Partners Maintains Trevi Therapeutics (TRVI) Outperform Recommendation - Nasdaq
TRVI's Price Target Raised by Leerink Partners to $16.00, Mainta - GuruFocus
0.45%
0.12%
자본화:
|
볼륨(24시간):